



1/67

FIG. 1 Flow of Patients Through the Trial




2/67

FIG. 2



3/67


FIG. 3.



*Median values:
 Age: 60 years
 PAV: 36.86
 TAV: 175.08
 Non-HDL: 115
 PCSK9: 315


4/67

FIG. 4A



5/67


FIG. 4B



6/67

FIG. 4C


Exploratory Subgroup: Baseline LDL-C <70 mg/dL



7/67


FIG. 4D

Exploratory Subgroup: Baseline LDL-C <70 mg/dL



8/67

FIG. 5



9/67

FIG. 6**alirocumab**

Heavy chain

EVQLVESGGG LVQPGGSLRL SCAASGFTFN NYAMNWVROA PGKGLDWVST 50
ISGSGGTTNY ADSVKGRFII SRDSSKHTLY LQMNSLRAED TAVYYCAKDS 100
NWGNFDLWGR GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKHTCPCP PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447 (SEQ ID NO: 4)

Light chain

DIVMTQSPDS LAVSLGERAT INCKSSQSVL YRSNNRNFLG WYQQKPGQPP 50
NLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQYYTT 100
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNMFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220 (SEQ ID NO: 5)

10/67

FIG. 7**bococizumab**

Heavy chain:

QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWRQA PGQGLEWMGE 50
ISPFGGRTNY NEFKSRVTM TRDTSTSTVY MELSSLRSED TAVYYCARER 100
PLYASDLWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVKRC CVECPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNATKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSGDS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 444 (SEQ ID NO: 6)

Light chain:

DIQMTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKPKAPKLLIYS 50
ASYRYTGVPV RFGSGSGTD FTFITSLQP EDIATYYCQQ RYSLWRTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214 (SEQ ID NO: 7)

11/67

FIG 8

Seq ID No.	LINE	V	D	J	FR1	CDR1	FR2
8		Germeline			QVQLVQSSAEVKRFQASVYVSCAS	GIYFTSYGIS	WVRQAPGQGLEWVQ
9	20D10	VR1-18		JH6B		-PI-	
10	26E10	VR1-18		JH6B			
11	21B12	VR1-18		JH6B			
12	23G1	VR1-18		JH6B			
13	26H5	VR1-18		JH6B			
14	27H5	VR1-18		JH6B			
15	31D1	VR1-18		JH6B			
16	27E7	VR1-18		JH6B			
17	30B9	VR1-18		JH6B		-PI-	
18	19H9	VR1-18		JH6B		-AI-	
19	17C2	VR1-18		JH6B		-S-	
20	25A7	VR1-18		JH6B			
21		Germeline			QVQLVQSSAEVKRFQASVYVSCAS	GIYFTSYGIS	WVRQAPGQGLEWVQ
22	3B6	VR1-18		JH4B			
23		Germeline			EVQLVESSGGNVFPGGSLRISCAS	QFTTSYVMS	WVRQAPGQGLEWVQ
24	8H6	VR3-7	D1-27	JH3A			
25	9C9	VR3-7	D7-27	JH3B			
26	1A12	VR3-7	D7-27	JH3B			
27		Germeline			EVQLVESSGGNVFPGGSLRISCAS	QFTTSYVMS	WVRQAPGQGLEWVQ
28	31H4	VR3-21	D3-3	JH3A		-JL-NE	
29		Germeline			EVQLVESSGGNVFPGGSLRISCAS	QFTTSYVMS	WVRQAPGQGLEWVQ
30		Germeline			EVQLVESSGGNVFPGGSLRISCAS	QFTTSYVMS	WVRQAPGQGLEWVQ
31	13B5	VR3-23		JH4B			

12/67

FIG. 9

Seq ID	LINE	V	D	J	FR1	CDR1	FR2
70		Germline			EVQLLESGGGLVQPGGSLALSCAAS	QPTFGSYGM	WVRQAPKGLRWVA
71	2385	VR3-33	D2-6	JH4B			
72	2504	VR3-23	D3-8	JH4B			
73		Germline			QVQLVESGGGVQPGGSLALSCAAS	QPTFGSYGM	WVRQAPKGLRWVA
74	3024	VR3-33		JH4B			
75		Germline			QVQLVESGGGVQPGGSLALSCAAS	QPTFGSYGM	WVRQAPKGLRWVA
76	27A6	VR3-33	D6-6	JH4B			
77	28B12	VR3-33	D6-6	JH4B			
289	28B12v1	VR3-33	D6-6	JH4B			
78	28D6	VR3-23	D6-6	JH4B			
79	16F12	VR3-33	D6-6	JH4B			
80	22E2	VR3-33	D6-6	JH4B			
81	31B12	VR3-33	D6-6	JH4B			
290	31B12v1	VR3-33	D6-6	JH4B			
82		Germline			QVQLVESGGGVQPGGSLALSCAAS	QPTFGSYGM	WVRQAPKGLRWVA
83	31G11	VR3-33	D6-19	JH4B			
84		Germline			QVQLQESGPGLVPSQTSLSLTCTVS	QSISGSSTWS	WTRQHPKGLRWIS
85	304	VR4-31		JH4B			
86		Germline			QVQLQESGPGLVPSQTSLSLTCTVS	QSISGSSTWS	WTRQHPKGLRWIS
87	27B2	VR4-31	D5-5	JH4B			
88		Germline			QVQLQESGPGLVPSQTSLSLTCTVS	QSISGSSTWS	WTRQHPKGLRWIS
89	31A4	VR4-34	D8-6	JH4B			
90		Germline			QVQLQESGPGLVPSQTSLSLTCTVS	QSISGSSTWS	WTRQHPKGLRWIS
91	13B1	VR6-1		JH4B			

13/67

FIG 10

Seq ID No.	LINE	CDR2	FR3	CDR3	FR4
8		WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
9	20D10	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
10	26E10	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
11	21E12	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
12	23G1	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
13	26H5	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
14	27H5	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
15	31D1	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
16	27E7	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
17	30B9	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
18	19B9	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
19	17C2	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
20	25A7	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
21		WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
22	3B6	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
23		WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
24	9H6	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
25	9C9	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
26		WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
27	1A12	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
28		WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
29	31H4	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
30		WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS
31	13E5	WISAYNGNTNYAQKIQG	KVTMTITSTSTAYNELSLASDDTAVYYCAR	YGMGV	WGQITIVTVSS

14/67

FIG 11

Seq ID No.	LINE	CDR2	FR3	CDR3	FR4
32		ATSGGSGSYTADSVRG	EPFISNDKSNKFLYLQMSLSRAEDTAVYYCAR	YLAIVIA DY	WQQTIVTVSS
33	23B5	T-----DN-----		KF-----ML-----	
34	25G4	T-----H-----		KF-----ML-----	
35		VIWYDSNKKYADSVRG	EPFISNDKSNKFLYLQMSLSRAEDTAVYYCAR	YTHGMDV	WQQTIVTVSS
36	30A4	-----D-----		ETGPKRL	
37		VIWYDSNKKYADSVRG	EPFISNDKSNKFLYLQMSLSRAEDTAVYYCAR	IAA QMDK	WQQTIVTVSS
38	27A6	L---S---D-----		AIRALYYVY	
39	28B12	L---N---D-----		AIRALYYVY	
40	28D6	L---N---D-----		AIRALYYVY	
41	16P12	L---S---D-----		AIRALYYVY	
42	22E2	L---N---D-----		AIRALYYVY	
43	22E2v1	L---N---D-----		AIRALYYVY	
44	31B12	L-----		RGGLARPG	
45	31B12v1	L-----		RGGLARPG	
46		VIWYDSNKKYADSVRG	EPFISNDKSNKFLYLQMSLSRAEDTAVYYCAR	SIAYATYYGMDV	WQQTIVTVSS
47	31G11	L---N---D-----		YLYGMDV	WQQTIVTVSS
48		VIYSGSGSYTNPGLAR	EVFISNDKSNKQFSLSLSSVTAASTAVYYCAR	GGVTT-----A-----	WQQTIVTVSS
49	3C4			EDINW YFDY	WQQTIVTVSS
50		YTYSGSGSYTNPGLAR	EVFISNDKSNKQFSLSLSSVTAASTAVYYCAR	-----P-----	WQQTIVTVSS
51	27B2	-----M-----		GGV P	WQQTIVTVSS
52		ETNRSSTNTPSLK3	EVFISNDKSNKQFSLSLSSVTAASTAVYYCAR	-----P-----	WQQTIVTVSS
53	31A4	-----N---D-----		FDY	WQQTIVTVSS
54		ETYYSGRWINDYAVSVRS	EVFISNDKSNKQFSLSLSSVTAASTAVYYCAR	GGETAA-----	WQQTIVTVSS
55	13H1	-----KN---D-----			

15/67

STRUCTURAL FORMULA

Heavy chain

EVQLVDSGAE	VKKPGASVKV	SCKASGYTLT	SYGISWVRQA	PGQGLERWGN	75
VSFENQNTNY	AGKLGGRGTN	TEDPETSTAY	NELESLREDD	TAVYVCARGY	100
GMDVWQCGTT	VTVSFASTKG	DSVFLAPCS	ESTFESTAAI	GCLVNDYFDE	125
PVTVSWNSIA	LTSQVHTFPA	VLQSSGLYSL	SSVVTWPSGN	TGTQFTTNV	150
DHFDENTKVD	KVERKOCVE	CEGCEAPFVA	GSVELFPEK	EDTFLMISPT	175
FEVDCVVVDV	SHEDSEVDFN	KYVDGVEVHN	ANTKPREEQF	NSTFRVVSVL	200
TVVHODWLNG	KEVRCFVSNK	GLPASIEKTI	SNTKCCPRFP	QVYTLFPGRE	225
ENTRNQVSLT	CLVKGFPYGD	IAVENESNGQ	PENNYKTEPE	MLSDGGSFFL	250
YSLTAVDKOR	WQQGVYFGCS	VMREALHNVY	TQKSLSLSPG	K	275 (SEQ ID NO: 56)

Light chain

ESALTQPAIV	SPSPGGSITI	STGTSSDIVG	GYNEVSWYQQ	HPGKAPKLMI	30
FEVSNRPSGV	SNRFGSKSG	NTASLTIEGL	QAEDEADYTC	NEYTRTSMVF	55
GGYTKLTVLG	QFNARPSVTL	FPSSSEELQA	NKATLVCLIS	LFYFGAVTYA	80
WRADSEPVKA	GVETTFPSKQ	SNNEVLAESY	LSLTFEQWKS	HRSYSCQVTH	105
EGSTVENTVA	PIEGG				130 (SEQ ID NO: 57)

Disulfide bridges

22'-90"	22"-90"	22-96	21"-96"	129-214	129"-214"
137-166	137"-166"	142-188	142"-188"	217-217"	218-218"
221-221"	224-224"	233-313	233"-313"	361-419	361"-419"

Glycosylation sites (Y)

Asn-291 Asn-291"

MOLECULAR FORMULA

 $C_{6242}H_{9648}N_{1058}O_{1896}S_{56}$

EVOLOCUMAB

FIG. 12

16/67

Constant Domains

Human IgG2:

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVT
 VPSSNFGTQTYTCNVDHKPSNTKVDKTVKCCVECPGPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTC
 VVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSFLTVMHGDWLNQKEYKCKVSNKGLF
 APIEKTISKAKGQPREPQVYTLPPSREEMITKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPMLD
 SDGSEFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPGK (SEQ ID NO: 58)

Human IgG4:

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVT
 VPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPCPCPAPEFLGCPVFLFPPKPKDTLMISRTPEVTC
 CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSFLTVMHGDWLNQKEYKCKVSNKGLF
 PSSIEKTISKAKGQPREPQVYTLPPSREEMITKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVL
 SDGSEFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSLGK (SEQ ID NO: 59)

Human lambda:

DPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNINKYAASSY
 LSLTPEQWKSRRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 60)

Human kappa:

TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
 TLTLTKADYERHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 61)

FIG. 13

17/67

QEDEDGDYEEELVLAIRSEEDGLAEAPEHGTTATFHBCAKDPWRLPGTYVVVLKEETHL
SOSERTARRLOAQAARRGYLTKEHVFIHGLLPGLVKMSGDLLELALKLPHVDYIEEDS
SVFAQSIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIBGRVMVTDEN
VPEEDGTRFHRRQASKCDSHGTHLAGVVSGRDAQYAKGASMRSLRVLNCQKGKGTVSGT
LIGLEFIRKSQVLVQPVGFLVVLPLAGGYSRVLNAACQRLARAGVVLVTAAGNFRDDAC
LYSPASAPEVITVGATNAQDQPVTLGTLGTNFGRCVDLEAPGEDIIIGASSDCSTCFVSQS
GTSQAAAHVAGIAAMMLSAEPFELTLAELRQRLIHFSKDVINEAWFPEDQRVLTPLVA
ALPPSTHGAGWQLPCRTVWSAHSGPTRMATAIARCAPDEELLSCSSFSRSGKRRGERME
AQGGKLVCRAHNAFGGEGVYAIARCCLLPQANCSVHTAPPAEASMGTKVHCHQQGHV
LTGCSSHWEVEDLGTHKPPVLRPRGQPNQCVGHREASIHASCCHAPGLECKVKEHGIPA
PQGQVTVACEEGWTLTGCSALPGTSHVLGAYAVDNTCVVRSRDVSTTGSTSEEAVTAV
AICCRSRHILAQASQELQ

SEQ ID NO:1

FIG. 14A

18/67

```

      10      20      30      40      50
Query  : atggggacacgtcagctccagggggtccctggtggcggctgccaactgctgct SEQ ID NO:2
Frame1 : M G T V S S R R S W W F L F L L L SEQ ID NO:3

      60      70      80      90     100
Query  : gctgctgctgctgctgctcctgggtccaggggcgcccgctggcaggaggagc
Frame1 : L L L L L L L S F A G A R A Q E E E

      110     120     130     140     150
Query  : agggagggcctactacagctagctggtgctagccttggctccaggaggagc
Frame1 : D G D Y E E L V L A L R S E E E

      160     170     180     190     200
Query  : ggcctggcgaagtcacccggagggagccacagccacattccacgcctc
Frame1 : G L A E A D E H Q Q T A T F H R C

      210     220     230     240     250
Query  : cgcacgggtccctggcgggtgctgggacctaactgggtggctggcggc
Frame1 : A K D F W R L P G E Y V V V L R E

      260     270     280     290     300
Query  : agggagcccccctatgccgagggagggcgccctgcacgcgcctggaggcc
Frame1 : E T K L S Q S E R F A R R L Q A

      310     320     330     340     350
Query  : caggctgcccgcaggggatccctcaccagcctctggatgctcttcctgg
Frame1 : Q A A R R S G Y L T K I L E V F R G

      360     370     380     390     400
Query  : ccttctctctggcttctctggagagagagctggcagctgctggagctgg
Frame1 : L L P G F L V K M S S D L L S L A

      410     420     430     440     450
Query  : ccttggaggtgcacccatgtccactatctgcaggaggacccctctgctttt
Frame1 : L E L P R V D Y I S E D S S V F

      460     470     480     490     500
Query  : gccagggcctcccgctggacccctggagtgattacccctccagggtacag
Frame1 : A Q K I P N N L E D I T F E R R R

      510     520     530     540     550
Query  : ggaggatgacacagagccacggagggaggcagctggtagagggtatcc
Frame1 : A D E Y G P P D S G D L V E V Y L

```

FIG. 14B1

```

      50          100          150          200          250
Query   : tccatgacacacagatcatcagagtcgacacacgggaactcgaaggcaggatc
Frame1  : L D T G I Q S S H R S I E G R V

      300          350          400          450          500
Query   : atgacacagacacttcagagatgagtcctcagagagcagggacccctctctc
Frame1  : M V T S F E N V W E E D C I N F H

      550          600          650          700          750
Query   : cagacacacagacagtcggcggcggcgcctggccacacacacatgacaggcagcgc
Frame1  : R Q A S K C G S E G T R L A G V V

      800          850          900          950          1000
Query   : tccagagcccgagatgacggcgctcggccagaggtgcccagcatcgaggccctg
Frame1  : S G R D A G V A K G A S M R S L

      1050          1100          1150          1200          1250
Query   : cggcgctgtcaactgcacagcgggaaggcgacagctaacggccacactctatgg
Frame1  : S V L R C Q G K G T V S G T L I G

      1300          1350          1400          1450          1500
Query   : cctggaggttactctgggaagagcggcggatggtcagatgtggggcactatgg
Frame1  : L S F I E K G Q L V Q P V S F L V

      1550          1600          1650          1700          1750
Query   : cgtgtcctctgagcctctggcgggtgggttaccagcggagctctccacagggccc
Frame1  : V L L P L A S D Y S R V L N A A

      1800          1850          1900          1950          2000
Query   : tgcacagcgcctggcggcggcggtctggggtctgttcgcttcaacgctgctggcga
Frame1  : C G R L K R A A G V V L V T R A D N

      2050          2100          2150          2200          2250
Query   : atctcggagcagatgctgtgctctactctccacagcctcagctctcccgagga
Frame1  : F R D D A C L Y E P A S A E E V E

      2300          2350          2400          2450          2500
Query   : tccacagtcggagccacacacatgcccagggacccagggcgggtaaccttgagga
Frame1  : T V G A T R A G D Q P V T L G T

      2550          2600          2650          2700          2750
Query   : ctggggcacaactcttgccgcttggtggcctctttgcacccagggggggg
Frame1  : L G T N T G R G V G L P A R G E D

```

FIG. 14B2

SUBSTITUTE SHEET (RULE 26)

21/67

```

      850      860      870      880      890      900
Query : caatgacacaaacagggcaacgtatcacaggctgcagctcaaatgga
Frame1 : H C R Q Q D H V E T Q C S S R W E

      950      960      970      980      990      1000
Query : agtggaggacattaggacacacaaaggcagcctgtctgagggcacaaggctc
Frame1 : V E S I G T H K E F V L R R R G Q

      1050      1060      1070      1080      1090      1100
Query : agctacacacgtgctatggtcacaggagagggcagctccagcttccctga
Frame1 : F N Q C V Q R D E A S I R A S C

      1150      1160      1170      1180      1190      1200
Query : tgcacagcacagagctcgggaatgaaagtcacaggagcaggaatccaggc
Frame1 : C H A P S L E C H V K E R G I P A

      1250      1260      1270      1280      1290      1300
Query : catcacagggcaggagacgtggcctgagaggaggctggacactgactg
Frame1 : F Q G Q V T V A C D S S W T L T R

      1350      1360      1370      1380      1390      1400
Query : gctgacagggcactcctcaggacacacacactcctgggggctacagctga
Frame1 : C S A L P Q T S H V L D A Y A V

      1450      1460      1470      1480      1490      1500
Query : gacacacagctctctcagggagcagggacgtcagcactacagggagcag
Frame1 : D R E E V Y S S R D V E T T E S T

      1550      1560      1570      1580      1590      1600
Query : cagcagagagagcagtgacacagcttgcactctgctgcaggagcagggcac
Frame1 : S E E S V T A P A I C C R S R R L


      1650      1660      1670      1680      1690      1700
Query : tggggcaggctctcagaggactcag
Frame1 : A Q A S Q S L Q

```

FIG 14B4

22/67


FIG. 15



23/67

Figure 16A and Figure 16B


A Primary Efficacy End Point



No. at Risk

Placebo	13,780	13,278	12,825	11,871	7610	3690	686
Evolocumab	13,784	13,351	12,939	12,070	7771	3746	689

B Key Secondary Efficacy End Point





No. at Risk

Placebo	13,780	13,449	13,142	12,288	7944	3893	731
Evolocumab	13,784	13,501	13,241	12,456	8094	3935	724

24/67


FIG. 17





26/67



FIG. 19



27/67

FIG. 20

A. Primary endpoint



28/67

FIG. 21





B. Key Secondary endpoint

FIG. 22



30/67

FIG. 23




Data from Cholesterol Treatment Trialists Collaboration (CTTC) are from *Lancet* 2010;376:1670-81

31/67

FIG. 24A


Primary Endpoint by PAD



32/67


FIG. 24B

CV Death, MI or Stroke by PAD



33/67


FIG. 25A

Major Adverse Limb Events – All Patients

34/67


FIG. 25B

Major Adverse Limb Events – Patients with PAD




35/67

FIG. 26

MACE or MALE by PAD

36/67

FIG. 27
Achieved LDL-C and Major Adverse Limb Events



37/67

FIG. 28

Cardiovascular Outcomes at 2.5 Yrs in Placebo Patients by Symptomatic PAD at Baseline




FIG. 29

CV Death, MI or Stroke at 2.5 Years in Placebo Patients by Disease State






FIG. 30

Cardiovascular Outcomes at 2.5 Yrs in Placebo Patients by Symptomatic PAD and no MI/Stroke at Baseline


40/67

FIG. 31

Limb Outcomes at 2.5 Yrs in Placebo Patients by Symptomatic PAD and no MI or Stroke at Baseline

41/67


FIG. 32

LDL Cholesterol by Treatment Group in Patients with Symptomatic Lower Extremity PAD

42/67

FIG. 33A


Primary Endpoint in Patients with PAD and no MI or Stroke



43/67

FIG. 33B

CV Death, MI or Stroke in Patients with PAD and no MI or Stroke



44/67

FIG. 33C




Major Adverse Limb Events – Patients with PAD and no MI or Stroke

FIG. 34

MACE or MALE in Patients with PAD and no MI or Stroke

46/67


FIG. 35

Achieved LDL-C and MACE or MALE in Patients with PAD

47/67

FIG. 36

Achieved LDL-C and MACE or MALE in Patients with PAD and no MI or Stroke



48/67




FIG. 37

49/67




FIG. 38

50/67




FIG. 39

51/67

Trial Design




FIG. 40

52/67

Primary Results




FIG. 41

53/67




FIG. 42 .




FIG. 43

55/67




FIG. 44

56/67

Benefit of EvoMab Based on Time from Prior MI




FIG. 45

57/67

Benefit of EvoMab Based on # of Prior MIs




FIG. 46

58/67

Benefit of EvoMab Based on Time from Prior MI




FIG. 47

59/67

Benefit of EvoMab Based on # of High-Risk MI Features




FIG. 48

60/67

Benefit of EvoMab Based on # of High-Risk MI Features




FIG. 49

61/67

Landmark Analyses in Pts w/ a High-Risk MI Feature




FIG. 50

62/67

Landmark Analyses in Pts w/ a High-Risk MI Feature




FIG. 51

63/67

TRS 2°P Variables	Points
CHF	1
HTN	1
Age≥75	1
DM	1
Prior Stroke	1
Prior CABG	1
PAD	1
eGFR<60	1
Current Smoking	1
Prior MI	1
Max Possible	10





FIG. 52

64/67



65/67




FIG. 54A

66/67




FIG. 54B

67/67




FIG. 55